177 related articles for article (PubMed ID: 19495750)
1. New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
Cereda V; Poole DJ; Palena C; Das S; Bera TK; Remondo C; Gulley JL; Arlen PM; Yokokawa J; Pastan I; Schlom J; Tsang KY
Cancer Immunol Immunother; 2010 Jan; 59(1):63-71. PubMed ID: 19495750
[TBL] [Abstract][Full Text] [Related]
2. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
3. ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
Sinnathamby G; Zerfass J; Hafner J; Block P; Nickens Z; Hobeika A; Secord AA; Lyerly HK; Morse MA; Philip R
Clin Exp Immunol; 2011 Mar; 163(3):324-32. PubMed ID: 21175594
[TBL] [Abstract][Full Text] [Related]
4. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
Smith HA; McNeel DG
J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
[TBL] [Abstract][Full Text] [Related]
6. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
7. NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells.
Das S; Hahn Y; Nagata S; Willingham MC; Bera TK; Lee B; Pastan I
Cancer Res; 2007 Feb; 67(4):1594-601. PubMed ID: 17308099
[TBL] [Abstract][Full Text] [Related]
8. Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.
Matsueda S; Wang M; Weng J; Li Y; Yin B; Zou J; Li Q; Zhao W; Peng W; Legras X; Loo C; Wang RF; Wang HY
PLoS One; 2012; 7(9):e45756. PubMed ID: 23029225
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
[TBL] [Abstract][Full Text] [Related]
10. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.
Guo J; Li G; Tang J; Cao XB; Zhou QY; Fan ZJ; Zhu B; Pan XH
Scand J Immunol; 2013 Sep; 78(3):248-57. PubMed ID: 23721092
[TBL] [Abstract][Full Text] [Related]
11. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M
Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796
[TBL] [Abstract][Full Text] [Related]
12. Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level.
Das S; Hahn Y; Walker DA; Nagata S; Willingham MC; Peehl DM; Bera TK; Lee B; Pastan I
Cancer Res; 2008 Aug; 68(15):6306-12. PubMed ID: 18676855
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis.
Mohsenzadegan M; Madjd Z; Asgari M; Abolhasani M; Shekarabi M; Taeb J; Shariftabrizi A
Cancer Immunol Immunother; 2013 Oct; 62(10):1609-18. PubMed ID: 23955683
[TBL] [Abstract][Full Text] [Related]
14. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein.
Kiessling A; Stevanovic S; Füssel S; Weigle B; Rieger MA; Temme A; Rieber EP; Schmitz M
Br J Cancer; 2004 Mar; 90(5):1034-40. PubMed ID: 14997204
[TBL] [Abstract][Full Text] [Related]
15. Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
Cancer Immunol Immunother; 2013 Dec; 62(12):1831-40. PubMed ID: 24149465
[TBL] [Abstract][Full Text] [Related]
16. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
17. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
Correale P; Walmsley K; Nieroda C; Zaremba S; Zhu M; Schlom J; Tsang KY
J Natl Cancer Inst; 1997 Feb; 89(4):293-300. PubMed ID: 9048833
[TBL] [Abstract][Full Text] [Related]
18. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
20. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.
Xue BH; Zhang Y; Sosman JA; Peace DJ
Prostate; 1997 Feb; 30(2):73-8. PubMed ID: 9051144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]